This finding is consistent with the results from one previous, nested case-control study, showing that ER−/HER2+ DCIS was associated with an increased risk of recurrent DCIS, but not with the risk of invasive recurrence [17]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.